ASSOCIATION BETWEEN SERUM MYOSTATIN LEVELS AND SARCOPENIA IN MIDDLE-AGED ADULTS: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.70520/kjms.v19i1.772Keywords:
Myostatin, Sarcopenia, Muscle mass, aging, physical activity, skeletal muscle massAbstract
Introduction: Myostatin levels in individuals increase with age, resulting in reduced muscle mass and decreased strength, which contributes to the development of sarcopenia.
Objectives: To find and compare the levels of Myostatin in middle-aged Sarcopenic and non-Sarcopenic individuals.
Materials and Methods: Material and Methods: This cross-sectional study employed purposive sampling and was conducted in the Department of Physiology at Khyber Medical University from October 26, 2023, to March 19, 2024. The OpenEpi software was used to determine the sample size with 80% power and a 95% confidence level. Ninety-two volunteers (male=58, female=34) were included in the study, which used the SWAG-SARCO 2021. Myostatin levels were measured using an enzyme-linked immunosorbent assay. The exercise tests were performed in the skill labs at IBMS, KMU, and BKMC Mardan.
Results: A statistically significant difference (p < 0.05) was observed between the patients in the Sarcopenia group and those in the non-Sarcopenia group regarding MUAC, TSF, CC, height, weight, and BMI. In addition, a statistically significant difference (p < 0.05) was also found between the sarcopenia group and the non-sarcopenia group in terms of SPPB, Grip strength, IRM-Knee extension, weightlifting, Quad stretch, and TUG test. The mean myostatin levels between the sarcopenic and non-sarcopenic groups were also statistically significant (p = 0.001).
Conclusion: This study showed that even among middle-aged individuals, myostatin levels may increase, leading to an involuntary loss of skeletal muscle strength and mass known as sarcopenia.
References
1. Boccardi V, Orr ME, Polidori MC, Ruggiero C, Mecocci P. Focus on senescence: Clinical significance and practical applications. J Intern Med. 2024;295(5):599–619.
2. Hu F-J, Liu H, Liu X-L, Jia S-L, Hou L-S, Xia X, et al. Mid-upper arm circumference as an alternative screening instrument to appendicular skeletal muscle mass index for diagnosing sarcopenia. Clin Interv Aging. 2021;1095–104.
3. Correa CHG, Mejía FM, González PAC, Claros JAV, Arroyabe HDC. Bioelectrical impedance analysis and dual x-ray absorptiometry agreement for skeletal muscle mass index evaluation in sarcopenia diagnosis. Physiol Meas. 2020;41(6):64005.
4. Bilski J, Pierzchalski P, Szczepanik M, Bonior J, Zoladz JA. Multifactorial mechanism of sarcopenia and sarcopenic obesity. Role of physical exercise, microbiota and myokines. Cells. 2022;11(01):160.
5. Ryan AS, Li G. Skeletal muscle myostatin gene expression and sarcopenia in overweight and obese middle?aged and older adults. JCSM Clin reports. 2021;6(4):137–42.
6. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12(8):2401.
7. Ryan AS, Li G, McMillin S, Prior SJ, Blumenthal JB, Mastella L. Pathways in skeletal muscle: Protein signaling and insulin sensitivity after exercise training and weight loss interventions in middle-aged and older adults. Cells. 2021;10(12):3490.
8. Landi F, Calvani R, Coelho-Junior HJ, Ciciarello F, Galluzzo V, Zazzara B, et al. Estimated appendicular skeletal muscle mass using calf circumference and mortality: Results from the aging and longevity study in the Sirente geographic area (ilSIRENTE study). Exp Gerontol. 2022;169:111958.
9. Park JE, Lee S, Kim K. The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea. BMC Geriatr. 2023;23(1):119.
10. Ackermans LLGC, Rabou J, Basrai M, Schweinlin A, Bischoff SC, Cussenot O, et al. Screening, diagnosis and monitoring of sarcopenia: When to use which tool? Clin Nutr ESPEN. 2022;48:36–44.
11. de Fátima Ribeiro Silva C, Ohara DG, Matos AP, Pinto ACPN, Pegorari MS. Short physical performance battery as a measure of physical performance and mortality predictor in older adults: a comprehensive literature review. Int J Environ Res Public Health. 2021;18(20):10612.
12. Pascual-Fernández J, Fernández-Montero A, Córdova-Martínez A, Pastor D, Martínez-Rodríguez A, Roche E. Sarcopenia: molecular pathways and potential targets for intervention. Int J Mol Sci. 2020;21(22):8844.
13. Cawthon PM, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, et al. Establishing the link between lean mass and grip strength cut points with mobility disability and other health outcomes: proceedings of the sarcopenia definition and outcomes consortium conference. Journals Gerontol Ser A. 2020;75(7):1317–23.
14. Zhang Y, Chen X, Hou L, Lin X, Qin D, Wang H, et al. Prevalence and risk factors governing the loss of muscle function in elderly sarcopenia patients: a longitudinal study in China with 4 years of follow-up. J Nutr Heal aging. 2020;24(5):518–24.
15. Yasar E, Tek NA, Tekbudak MY, Yurtda? G, Gülbahar Ö, Uyar GÖ, et al. The relationship between myostatin, inflammatory markers, and sarcopenia in patients with chronic kidney disease. J Ren Nutr. 2022;32(6):677–84.
16. Lena A, Anker MS, Springer J. Muscle wasting and sarcopenia in heart failure—the current state of science. Int J Mol Sci. 2020;21(18):6549.
17. Sakthivadivel V, Geetha J, Gaur A, Kaliappan A. Performance-Oriented Mobility Assessment test and Timed Up and Go test as predictors of falls in the elderly–A cross-sectional study. J Fam Med Prim care. 2022;11(11):7294–8.
18. McLay R, Kirkwood RN, Kuspinar A, Richardson J, Wald J, Raghavan N, et al. Validity of balance and mobility screening tests for assessing fall risk in COPD. Chron Respir Dis. 2020;17:1479973120922538.
19. Li C, Yu K, Shyh?Chang N, Jiang Z, Liu T, Ma S, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022;13(2):781–94.
20. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. Nutrients. 2021;13(10):3519.
21. Oliveira PGS, Schwed JF, Chiuso-Minicucci F, Duarte SRS, Nascimento LM, Dorna MS, et al. Association between serum myostatin levels, hospital mortality, and muscle mass and strength following ST-elevation myocardial infarction. Hear Lung Circ. 2022;31(3):365–71.
22. Kurose S, Onishi K, Takao N, Miyauchi T, Takahashi K, Kimura Y. Association of serum adiponectin and myostatin levels with skeletal muscle in patients with obesity: A cross-sectional study. PLoS One. 2021;16(1):e0245678.
23. Carvalho LP, Basso-Vanelli RP, Di Thommazo-Luporini L, Mendes RG, Oliveira-Junior MC, de Paula Vieira R, et al. Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults. Cytokine. 2018;107:118–24.
